Cu-ATSM appears superior in terms of imaging performance, calling for industrial and clinical development of this innovative radiopharmaceutical.
Introduction
During the carcinogenesis process of a wide range of solid tumours, tumour cells often have a more rapid proliferation potential than the cells that form blood capillaries by neoangiogenesis.
As a consequence of this poorly organized vasculature, a hypoxia area is often observed due to the limited delivery of oxygen ( Figure 1 ) in a population of cells distant from blood vessels (> 100 mm from the closest blood vessel [1] ).
Hypoxia in the tumour microenvironment is an extensively studied parameter because this lack of oxygen has negative implications for clinical outcome. The effects of hypoxia are related to two major events: 1 -hypoxia raises genetic instability and more aggressive phenotypes with bad prognosis for patients, and 2 -hypoxic cells are more resistant to radiotherapy and chemotherapy treatments (consequence of poor vascularization [2] ). The increased resistance to radiotherapy ( Figure 2 ) has been particularly studied in head and neck cancers and cervical carcino- Review mas [3, 4] and is associated with the loss of oxygen enhancement effect during radiotherapy.
The radiobiological mechanism by which ionizing radiations kill cells is mostly based on DNA damage, particularly DNA double strand breaks. This damage results from ionization either in or very close to the DNA molecule, producing a radical on the DNA (DNA Ÿ ). This radical is then engaged either in an oxidation process into aerobic cells resulting in permanent damage, or in a reduction process into hypoxic cells [5] mostly by thiol-containing compounds that can restore DNA and lead to tumour cell survival.
Over the years, several different methods have been developed to assess the in vivo hypoxic level of tumours. The polarographic oxygen electrode (most commonly known as the "Eppendorf electrode") was used as the gold standard and has been extensively employed for quantifying hypoxia at different positions in tumours and within a short time frame in both animal studies and human tumours [6, 7] . However, this method presents some major drawbacks. It is an invasive technique limited to accessible tumours with sufficient size with a risk of tissue disruption and is known to present large inter-observer variability [8] . Another invasive method based on biopsy immunohistochemical analysis of hypoxia-inducing factors-1a (HIF-1a) is used to investigate the hypoxia status of tumours. HIF-1a is the major transcription factor of genes that are involved in angiogenesis, glucose metabolism, cell proliferation/survival, and invasion/metastasis and was found overexpressed in human cancers as a result of intratumoural hypoxia [9] .
In recent decades, investigations into alternative, non-invasive imaging methods for measuring pO 2 have been studied [10] . The use of positron emission tomography (PET) has led to a number of promising positron emitter radiopharmaceuticals [11] [12] [13] Zn (9.2 hours), but the major drawback is the small cross section of the 62 Zn cyclotron production leading to an important production cost which will limit its clinical use. Fur- Ni(p,n) 64 Cu nuclear reaction. This cyclotron reaction requires a proton beam of about 11 MeV and presents a good production yield with a cross section of about 700 mbarn [15, 16] . With the ARRONAX cyclotron (a high energy and high intensity multi-particle accelerator located in Nantes, France) another reaction route, 64 Ni (d,2n), is used. The excitation function looks attractive, with a maximum cross section of 800 mbarn at 16 MeV [18] . Targets are made of enriched 64 Ni (more than 96%) electroplated onto gold backing. Since 64 Ni is expensive, it is necessary to recycle it in order to reduce costs.
Moreover, a comparison of cross section data between the two reaction routes points out a good yield for the 64 Ni(d,2n) reaction with a thinner deposit of 64 Ni, which reduces cost too [19] . The physical characteristics of these two isotopes are given in Table 2 .
Radiopharmaceutical labelling
To date, the most commonly used route for radiolabelling followed by the hydrolysis of the protecting group with 1M HCl [20] .
The synthesis procedure is summarized in Figure 3A .
The classical way to prepare [
64 Cu]-diacetyl-bis(N 4 -methylthiosemicarbazone) (= [
64 Cu]-ATSM) is the addition of 1.5 ml of 1 M sodium acetate on the dry residue of purified copper chloride (CuCl 2 ) followed by the addition of H 2 -ATSM in DMSO [21] . The synthesis procedure is summarized in Figure 3B .
In terms of international pharmaceutical regulations, both chemical precursors (NITTP and H 2 -ATSM are considered as raw materials) for radiolabelling can be purchased from companies that manufacture these products according to good manufacturing practice requirements for active pharmaceutical ingredients for use in clinical trials (International Conference on Harmonisation Q7 chapter 19).
Currently the two radiopharmaceuticals can be prepared by a fully automated procedure in sufficient amounts for clinical practice, with a radiochemical purity greater than 95%, giving a final product that fulfils the criteria of radiopharmaceutical quality (in terms of radionuclidic purity, sterility, and bacterial endotoxin analysis) [20, 21] . Briefly, after entering a viable cell, nitroimidazole compounds, like [ 18 F]-FMISO, are reduced to RNO 2 radicals, regardless of the intracellular oxygen level. In the presence of oxygen, the radical is immediately reoxidized, and [
Pharmacological mechanism of radiotracer uptake
18 F]-FMISO leaves the cell. However, if the intracellular oxygen concentration is low, the RNO 2 radicals are further reduced to RNHOH compounds that bind covalently to intracellular macromolecules and remain within the cell [22, 23] .
[64Cu]-ATSM [25] [26] [27] . In vitro studies have demonstrated that the accumulation time in normoxic cells was two to nine times lower than that in hypoxic cells, depending upon cell line [28] . This explains why, in clinical practice, despite the fact that the ATSM-copper complex is taken up in normoxic cells, a good image contrast is obtained.
Patient dosimetric data
The classical injected activity for a PET image of tumour hypoxia is about 3. with thallium-201 in stress and rest cardiac imaging [33] and the liver irradiation observed for an abdomen multidetector CT scan procedure (11.5 mSv for a tissue weighting factor of 0.04) [34] .
Clinical imaging of hypoxia
The first report on the use of [
18 F]-FMISO in humans was published in 1992 for three patients with malignant glioma [35] . In 1996, a study assessed the level of hypoxia in a variety of human cancers (37 patients with non-small cell lung cancer, head and neck tumours, prostate tumours, cervical carcinoma, rectal carcinoma, metastatic breast carcinoma, thyroid carcinoma, or metastatic renal cell carcinoma) and concluded that human tumour hypoxia was widely prevalent and highly variable between tumours with the same histology and also between regions within the same tumour [36] . Tissue hypoxia has been determined by PET imaging and quantified in terms of contrast based on tissue-to-blood ratio (T/B) higher than 1.2, 2 hours after radiopharmaceutical administration [37] . Different studies compared [ 18 F]-FMISO uptake with pO 2 measurement from an "Eppendorf electrode" and confirmed, with a good correlation, the use of [
18 F]-FMISO PET to measure hypoxia in renal cell carcinoma and head and neck cancer but not on human soft tissue tumours [38] . Several clinical studies have used [
18 F]-FMISO as a prognostic indicator for the survival of a number of patients. The kinetic behaviour of [ 18 F]-FMISO in tumour tissue allowed a good prediction of patient outcome after radiotherapy and prediction of freedom from disease as well as overall survival [39] . This threshold value differentiated patients whose cancer did not recur from those who developed a recurrence after complete therapy [41] . A PET study conducted in patients suffering from cervical cancer comparing [
64 Cu]-ATSM uptake with tissue molecular markers of hypoxia (vascular endothelial growth factor, cyclo-oxygenase-2, epidermal growth factor, carbonic anhydrase IX) confirmed a good correlation between quantitative PET image and overexpression of the hypoxia molecular factors [42] . -low tumour-to-background ratios due to non-specific binding resulting from its relatively high lipophilicity; -significant non-oxygen dependent metabolism leading to a considerable amount of radioactive metabolites; -intra-tumoural large uptake variability.
In conclusion, [
64 Cu]-ATSM has several advantages over other radiopharmaceuticals used for PET of hypoxia, including a simple and rapid method for radiolabelling, faster clearance from normoxic tissues (allowing a short time between injection and imaging), a simple method for quantification, and very good image quality. In various clinical trials, [
64 Cu]-ATSM provided images of tumour hypoxia that improved the clinical outcome of patients submitted to external beam radiotherapy. The sum of these advantages seems to overcome the less favourable dosimetry of this radiopharmaceutical, and -in conclusion -[
64 Cu]-ATSM seems to be a good radiopharmaceutical candidate that can be used to obtain high quality images of tumour hypoxia.
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